EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza

Pauline Vetter iD, Ana Rita Goncalves Cabecinhas, Manuel Schibler, Laurent Kaiser, Karen Cruz-Fauquex, Yves Chalandon, Stavroula Masouridi-Levrat, Dionysios Neofytos

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01659-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Pauline Vetter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Geneva Center for Emerging Viral Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland. Hauptthemen laut MEDLINE: Antiviral Agents, Dibenzothiepins, Influenza, Human, Triazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Emerging Viral Diseases, Geneva University Hospitals, Laboratory of Virology, Diagnostics Department, Geneva University Hospitals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunocompromised patients are at risk of developing severe influenza, with protracted viral shedding and development of resistance-associated mutations under antiviral treatment. We report a case series of severely immunocompromised hematology patients, including allogeneic hematopoietic cell transplantation (HCT) recipients, treated with both baloxavir and oseltamivir and describe clinical and virological outcomes and the safety profile of prolonged combination therapy. Allogeneic HCT recipients with influenza infection treated with baloxavir were retrieved via institutional databases. All hospitalized allogeneic HCT patients treated with a combination therapy of baloxavir and oseltamivir over five influenza seasons between October 2019 and May 2025 were included. Six influenza-infected hematology patients (5/6 allogeneic HCT recipients) were treated with combination therapy of oseltamivir and baloxavir. All patients presented with lower respiratory tract infections. Oseltamivir treatment duration ranged from 5 to 31 days, and the number of administered baloxavir doses ranged between one and five. Baloxavir administration was well tolerated, and no adverse events could be attributed to the administered antiviral treatment. All-cause mortality at 3 months post-infection was 66% (4/6), mainly driven by underlying disease. In two patients with protracted shedding, combination therapy did not prevent the development of resistance mutation(s). Combination treatment with prolonged courses of oseltamivir and repeated doses of baloxavir was well tolerated. No definitive conclusions on the efficacy of this approach could be drawn from this study. More data are required on the best treatment of hematology patients infected with influenza.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDibenzothiepinsInfluenza, HumanTriazinesMorpholinesPyridonesOseltamivirNeuraminidaseEnzyme InhibitorsThiepinsHumansFemaleMaleImmunocompromised HostMiddle AgedAdultDrug Resistance, ViralDrug Therapy, CombinationHematopoietic Stem Cell TransplantationAged

Stichwörter der Autor:innen

HCTbaloxavircombination therapycomplicationsimmunosuppressioninfluenzamortalityoseltamivirsafetytreatment

Substanzen

baloxavirAntiviral AgentsDibenzothiepinsTriazinesMorpholinesPyridonesOseltamivirNeuraminidaseEnzyme InhibitorsThiepins

Autor:innen und Institutionen

  • Geneva Center for Emerging Viral Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland.
  • Division of Infectious Diseases, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland.
  • Laboratory of Virology, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.
  • National Reference Center of Influenza, Geneva University Hospitals, Geneva, Switzerland.
  • Pharmacy, Geneva University Hospitals, Geneva, Switzerland.
  • Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.

ORCID-Profile: Pauline Vetter

Förderung

  • Center for Emerging Viral Diseases, Geneva University Hospitals
  • Laboratory of Virology, Diagnostics Department, Geneva University Hospitals

Zitieren

APA

Vetter, P., Cabecinhas, A. R. G., Schibler, M., Kaiser, L., Cruz-Fauquex, K., Chalandon, Y., Masouridi-Levrat, S., & Neofytos, D. (2026). Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01659-25

Vancouver

Vetter P, Cabecinhas ARG, Schibler M, Kaiser L, Cruz-Fauquex K, Chalandon Y, et al. Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01659-25

BibTeX
@article{Vetter2026,
  author = {Vetter, Pauline and Cabecinhas, Ana Rita Goncalves and Schibler, Manuel and Kaiser, Laurent and Cruz-Fauquex, Karen and Chalandon, Yves and Masouridi-Levrat, Stavroula and Neofytos, Dionysios},
  title = {Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01659-25}
}
Kostenlos starten →